Navigation Links
Abbott to Subsidize Price of HIV Drug

The US-based pharmaceutical multi-national, the Abbott, has agreed to lower the prices of Kaletra/Aluvia in low and low-middle income countries to one thousand// US dollars, on a request from the World Health Organization’s Director-General Margaret Chan.

Kaletra is indicated for the treatment of HIV-1 infected adults and children above the age of 2 years, in combination with other antiretroviral agents. It is in a category of HIV medicines called protease inhibitors (PIs).

Protease is a chemical, known as an enzyme that HIV needs in order to make new viruses. Protease inhibitors (PIs) block the protease enzyme. When protease is blocked, HIV makes copies of itself that cannot infect new cells.

Kaletra is actually two drugs combined into a single capsule: lopinavir and low doses of ritonavir, another protease inhibitor manufactured by Abbott Laboratories.

In some parts of the world, these Kaletra tablets are sold under the brand name Aluvia.

To meet the needs of countries committed to expanding HIV/AIDS treatment, Abbott will offer the governments of more than 40 low and low-middle income countries (as defined by World Bank criteria) and NGOs a new price of $1,000 per patient per year.

This price is lower than any generic price available in the world today for this medicine and is approximately 55 percent less than the average current price for these countries, the press release states.

Abbott will immediately begin discussions with individual countries where Abbott's patents are respected to maximize the number of patients that can be provided Kaletra/Aluvia capsules and tablets at this new price.

At the same time the Abbott affirmed that the patents of scientists and inventors must exist so that there were incentives for sustained research and development. Without this system, the miracle drugs the world enjoys today, including HIV medicines, would not exist, it said.

Specifically, with regard to Thailand, Abbott appreciated and fully respected the suggestion of Director-General Chan that more work needed to be done with the government of Thailand to achieve a positive outcome. Meanwhile, Kaletra capsules would be in Thailand and eligible for the new price.

Today, Kaletra capsules are registered in 118 countries.
GPL/B
'"/>




Related medicine news :

1. Pharmacia may take 51.5 percent Abbott stake
2. Abbott Laboratories to buy Biocompatibles cardiovascular stent business
3. Abbott’s Laboratories R&D Capabilities Questione
4. Abbott Receives CE Mark Certification
5. Abbott Offers Aluvia to Thailand in Return for Compulsory Licensing Halt
6. Herceptin Subsidized By Australian Government
7. Cervical Cancer Vaccine Gardasil Included In Subsidized CDC program
8. Drug Prices in India to be Monitored - NPPA to Tie up with ORG
9. Price Of Alcohol Does Not Influence Consumption
10. Delhi Sees Sharp Decline In Chicken Prices
11. Prices of eggs, egging its way upwards
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/17/2017)... , ... January 17, 2017 , ... A prescription medication ... of the fourth Cradle to Cradle Product Design Challenge , the Cradle ... a series of six circular design challenges scheduled to run through early 2018. The ...
(Date:1/17/2017)... ... January 17, 2017 , ... Wettstein ... to families and business professionals throughout central Colorado, is joining local nonprofit Aurora ... The Aurora Warms The Night organization is committed to breaking the cycle of ...
(Date:1/17/2017)... ... January 17, 2017 , ... Seceon , the ... in real-time, today announced a strategic partnership with TechLab Security, a ... Seceon partners, TechLab Security has become a strategic partner and a value added ...
(Date:1/17/2017)... New York, NY (PRWEB) , ... January 17, ... ... of Inc. Magazine’s fastest-growing private companies and ranked among the top US security ... first Board of Directors. This announcement brings a year-long independent board nomination ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... the Montclair State University’s Athletic Training Education program forged a relationship built upon ... Education Program, which is consists of both student members and certified members ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... GRAND RAPIDS, Mich. , Jan. 17, 2017 ... of Richard M. Erwin as Vice ... Catalyst Pharmaceuticals, where he was Executive Director, Clinical Project Management. ... with over 25 years of experience in global ... a string of successful growth-stage clinical operation build-outs ...
(Date:1/17/2017)...  Bayer today announced the appointment of Dr. Carsten ... Americas, comprising the United States , ... . In this role, Dr. Brunn will report to ... of Bayer AG and President of the Pharmaceutical division. ... the pharmaceutical industry and I,m delighted to have him lead ...
(Date:1/16/2017)... 2017 Research and Markets has announced the ... report to their offering. ... Global multiple myeloma drugs market to grow at a ... report covers the present scenario and the growth prospects of the ... size, the report considers the revenue generated from the sales of ...
Breaking Medicine Technology: